DMTK - DermTech Inc Stock Price, Fair Value and News

$55.65

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DMTK Price Action

DMTK RSI Chart

DMTK Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-21.71

Price/Sales (Trailing)

124.21

Price/Free Cashflow

-26.94

DMTK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DMTK Fundamentals

DMTK Revenue

Revenue (TTM)

15.7M

Rev. Growth (Yr)

10.58%

Rev. Growth (Qtr)

-2.01%

DMTK Earnings

Earnings (TTM)

-89.6M

Earnings Growth (Yr)

36.01%

Earnings Growth (Qtr)

-4.81%

DMTK Profitability

Operating Margin

8.51%

Return on Equity

-224.1%

Return on Assets

-87.04%

Free Cashflow Yield

-3.71%

DMTK Investor Care

Shares Dilution (1Y)

12.46%

Diluted EPS (TTM)

-2.66

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.7M	0	0	0
2023	14.3M	14.0M	14.4M	15.3M
2022	13.0M	14.1M	14.7M	14.5M
2021	6.9M	9.1M	10.8M	11.8M
2020	4.3M	4.6M	5.4M	5.9M
2019	2.5M	2.5M	2.4M	3.4M
2018	1.2M	1.6M	2.0M	2.4M
2017	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About DermTech Inc

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

CEO	Mr. Bret Christensen
WEBSITE	dermtech.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	278

DermTech Inc Frequently Asked Questions

What is the ticker symbol for DermTech Inc? What does DMTK stand for in stocks?

DMTK is the stock ticker symbol of DermTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DermTech Inc (DMTK)?

As of Mon Sep 02 2024, market cap of DermTech Inc is 1.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DMTK stock?

You can check DMTK's fair value in chart for subscribers.

Is DermTech Inc a good stock to buy?

The fair value guage provides a quick view whether DMTK is over valued or under valued. Whether DermTech Inc is cheap or expensive depends on the assumptions which impact DermTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMTK.

What is DermTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Sep 02 2024, DMTK's PE ratio (Price to Earnings) is -21.71 and Price to Sales (PS) ratio is 124.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMTK PE ratio will change depending on the future growth rate expectations of investors.